Management of pregnancy in antiphospholipid syndrome

Rheumatic Disease Clinics of North America

Volumn 27, Issue 3, 2001, Pages 643-659

  Shehata, Hassan A ^a,b   Nelson Piercy, Catherine ^a   Khamashta, Munther A ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST HELIER HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; HEPARIN; IMMUNOGLOBULIN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; FETUS WASTAGE; HIGH RISK POPULATION; HUMAN; MATERNAL MORBIDITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOSIS;

EID: 0034872052     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70226-X     Document Type: Article

References (109)

1. The cell biology of human implantation
2. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin
3. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3)
4. Low-dose aspirin for prevention of pregnancy losses in women with antiphospholipid syndrome
5. Antiphospholipid antibodies in pregnancy
6. Induction of antiphospholipid syndrome in naïve mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies
7. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy
8. The association of antiphospholipid syndrome with severe pre-eclampsia
9. Autoimmune disease
10. Clinical implications of antiphospholipid antibodies: The Utah experience
11. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis
12. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
13. Obstetric complications associated with lupus anticoagulant
14. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience
15. A study of 100 high risk lupus pregnancies
16. Trophoblast migration during human placental implantation
17. Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome
18. Effect of antioxidants on the occurrence of preeclampsia in women at increased risk: A randomised trial
19. Mid-trimester uterine artery Doppler screening as a predictor of adverse pregnancy outcome in high-risk women
20. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisolone with low-dose heparin treatment
21. Do low-risk pregnant women with antiphospholipid antibodies need to be treated?
22. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
23. Underlying disorders associated with severe early-onset pre-eclampsia
24. Prolonged heparin therapy in pregnancy causes bone demineralization
25. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
26. Antiphospholipid antibodies affect trophoblast gonadotrophin secretion and invasiveness by binding directly and through adhered β2-glycoprotein I
27. Low-dose aspirin in pregnancy
28. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy
29. Relation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with systemic lupus erythematosus
30. Antiphospholipid syndrome in pregnancy: A controlled treatment trial
31. Human cytotrophoblast invasion
32. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin 3
33. Anti-prothrombin antibodies and the lupus anticoagulant
34. Plasma exchange and the anticardiolipin syndrome in pregnancy
35. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor
36. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases
37. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome
38. Obstetric outcome in antiphospholipid syndrome
39. The trophoblast as an integral component of a macrophage-cytokine network
40. Doppler ultrasound of the uterine arteries: The importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby
41. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test
42. Cerebral infarctions associated with lupus anticoagulants
43. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: Is warfarin preferable?
44. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies
45. 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome
46. Pregnancy in systemic lupus erythematosus. Contraception, fetal outcome and congenital heart block
47. β2-glycoprotein I: Target antigen for autoantibodies in the antiphospholipid syndrome
48. Specific antiphospholipid antibodies (aPL) eluted from placenta of pregnant women with aPL-positive sera
49. Lupus anticoagulant and pregnancy
50. Early Doppler studies in lupus pregnancy
51. The management of thrombosis in the antiphospholipid-antibody syndrome
52. Pregnancy-associated osteoporosis
53. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome
54. Antiphospholipid antibody-associated recurrent pregnancy loss-treatment with heparin and low-dose aspirin is superior to low-dose Aspirin along
55. Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome
56. Adverse pregnancy outcome in antiphospholipid syndrome: Focus for future research
57. Growth factors, proteases and protease inhibitors in the maternal-fetal dialogue
58. Antiphospholipid syndrome in pregnancy
59. Prednisolone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
60. Lupus anticoagulants and thrombosis: A study of 25 cases and review of the literature
61. A study of sixty pregnancies with the antiphospholipid syndrome
62. Uterine artery velocimetry in relation to trophoblast migration into the myometrium of the placental bed
63. Which patients with antiphospholipid antibody should be treated and how?
64. Prednisolone does not prevent recurrent fetal death in women with antiphospholipid antibody
65. The immunology and obstetrical consequences of antiphospholipid antibodies
66. Antiphospholipid antibody and pregnancy wastage
67. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin in a general obstetric population
68. Fetal survival after prednisolone suppression of maternal lupus anticoagulant
69. Lupus anticoagulant in pregnancy
70. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study
71. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages
72. Is warfarin sodium contraindicated in the lactating mother?
73. Human trophoblast invasion, autocrine control and paracrine modulation
74. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts
75. The prevalence of autoantibodies during thirdtrimester pregnancy complicated by hypertension or idiopathic fetal growth retardation
76. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia
77. Heparin-induced osteoporosis in pregnancy
78. Low molecular weight heparin for prophylaxis of thromboembolic disease during pregnancy
79. Low molecular weight heparin for obstetric thromboprophylaxis: Experience of 69 pregnancies in 61 high risk women
80. Maternal and fetal sequelae of anticoagulation during pregnancy
81. May mothers given warfarin breast-feed their infants?
82. Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations
83. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial
84. Anti-cardiolipin antibodies in unselected pregnant women in relationship to fetal outcome
85. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
86. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies
87. Pregnancy outcome and anticardiolipin antibody in women with systemic lupus erythematosus
88. Pregnancy outcome-influence of antiphospholipid antibody titer, prior pregnancy loss and treatment
89. Anaesthesia and antiphospholipid syndrome-a review of 20 obstetric patients
90. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies
91. A prospective study of 53 consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibodyrelated fetal loss
92. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves
93. Safety of low-molecular-weight heparin in pregnancy: A systematic review
94. Anti-cardiolipin antibodies and preeclampsia
95. Comparative trial of prednisolone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody positive obstetric patients
96. Recurrent miscarriage: Autoimmune considerations
97. Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies
98. Antiphospholipid antibodies in pre-eclamptic women: Relation to growth retardation and neonatal outcome
99. Osteoporosis of pregnancy
100. Pregnancy-associated osteoporosis
101. Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus
102. Hazards of oral anticoagulants during pregnancy
103. Epithelial-mesenchymal transition during trophoblast differentiation
104. Dose dependent fetal complications of warfarin in pregnant women with mechanical heart valves
105. A model for the antiphospholipid antibody syndrome: Monoclonal antiphosphotidylserine antibody induces intrauterine growth restriction in mice
106. International consensus statement on preliminary classification criteria for antiphospholipid syndrome: Report of an international workshop
107. Studies on the association between the anticardiolipin antibody and pre-eclampsia
108. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy